Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC1130A in Sanfilippo Syndrome Type A
NCT06567769Phase 1Active, not recruiting
- Sponsor
- GC Biopharma Corp
- Start
- Nov 2024
- Primary completion
- Jun 2027
- Modality
- Replacement Enzymes
- Countries
- 2
01
Overview
Phase 1, open-label trial of recombinant human heparan-N-sulfatase in Sanfilippo syndrome type A (3 cohorts), sponsored by GC Biopharma Corp. Primary endpoint: Incidences and characteristics of adverse events at 108 weeks. Started Nov 2024; status: active, not recruiting.
02
Drugs
recombinant human heparan-N-sulfatase
03
Conditions
Sanfilippo syndrome type A
Beyond the preview
Go deeper on NCT06567769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06567769.